MedTrace Logo

uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer

NCT02805608 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-04-11

No results posted yet for this study

Summary

The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer

Conditions

  • Urinary Bladder Neoplasms

Interventions

DRUG

Injection of 68Ga-NOTA-AE105

One injection intravenously of 68Ga-NOTA-AE105

DRUG

Injection of 18F-FDG

One injection intravenously of 18F-FDG

DEVICE

Positron Emission Tomography and CT

Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection

DEVICE

Positron Emission Tomography and MRI

Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Dorthe Skovgaard, Md, PhD · Rigshospitalet, Denmark

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02805608 on ClinicalTrials.gov